Form 13-F position report

CYTOKINETICS INC

Reported by Sarissa Capital Management LP

CYTK CUSIP 23282W605 Manager CIK 0001577524

Reported 228,623 shares, unchanged from the prior quarter.

Reported value -22.6%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 9.84% This manager · Q3 2026
Shares 228,623 Quarter-end amount reported
Reported value $15,068,542 Fair value at quarter end
Consecutive quarters held 11 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2024-03-31 21033000
2024-06-30 60139800
2024-09-30 58608000
2024-12-31 39221905
2025-03-31 24114000
2025-06-30 19439315
2025-09-30 32336101
2025-12-31 25184524
2026-03-31 15068542
2026-06-30 19476393
2026-09-30 15068542

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for CYTOKINETICS INC held by Sarissa Capital Management LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 228,623 0 (0.0%) 9.84% $15,068,542 2026-11-16
Q2 2026 Unchanged 228,623 0 (0.0%) 10.95% $19,476,393 2026-08-14
Q1 2026 Reduced 228,623 -167,734 (-42.3%) 9.56% $15,068,542 2026-05-15
Q4 2025 Reduced 396,357 -192,000 (-32.6%) 11.3% $25,184,524 2026-02-17
Q3 2025 Unchanged 588,357 0 (0.0%) 17.93% $32,336,101 2025-11-14
Q2 2025 Reduced 588,357 -11,643 (-1.9%) 12.59% $19,439,315 2025-08-14
Q1 2025 Reduced 600,000 -233,799 (-28.0%) 15.59% $24,114,000 2025-05-15
Q4 2024 Reduced 833,799 -276,201 (-24.9%) 12.15% $39,221,905 2025-02-14
Q3 2024 Unchanged 1,110,000 0 (0.0%) 14.57% $58,608,000 2024-11-14
Q2 2024 Added 1,110,000 +810,000 (270.0%) 10.15% $60,139,800 2024-08-14
Q1 2024 New 300,000 +300,000 (0.0%) 3.68% $21,033,000 2024-05-15

Who else reported the position

538 managers reported CYTOKINETICS INC for Q3 2026.

Managers reporting CYTOKINETICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 21,041,152 +946,790 0.02% $1,386,822,344 9 qtrs
T Rowe Price Investment Management Inc Added 18,912,704 +194,206 0.88% $1,246,537,000 16 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 10,590,381 +3,658,611 0.12% $698,012,012 26 qtrs
STATE STREET CORPORATION Added 7,143,229 +648,996 0.01% $470,810,223 54 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 6,799,536 +87,737 0.02% $448,157,418 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 6,266,419 +148,904 < 0.01% $413,019,676 3 qtrs
Avoro Capital Advisors LLC Reduced 4,900,000 -99,999 3.33% $322,959,000 3 qtrs
Bank of America Corporation Added 4,735,328 +99,619 0.02% $312,105,470 53 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 3,767,864 +55,363 0.01% $248,385,218 54 qtrs
Polar Capital Holdings Plc Added 9,635,314 +7,381,665 0.55% $227,685,323 24 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
228,623
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.